<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383588</url>
  </required_header>
  <id_info>
    <org_study_id>2017- 8094</org_study_id>
    <nct_id>NCT03383588</nct_id>
  </id_info>
  <brief_title>Subcutaneous Bupivacaine Decrease Post-op Pain in Patients Undergoing C-Section</brief_title>
  <official_title>Addition of Subcutaneous Bupivacaine to Patients Undergoing Cesarean Section for Post-op Pain Relief, Receiving Intrathecal Morphine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Camparing post-op pain scores and oxycodone usage in patients who receive jsut intrathecal
      morphine to patients who receive intrathecal morphine plus subcutaneous bupivacaine .25%, to
      patients who receive bupivacaine .25% with epinephrine 1:200,000. Oxycodone usage and pain
      scores
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of supplemental oxycodone added</measure>
    <time_frame>how much oxycodone first 4-24 hours post op</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Pain, Referred</condition>
  <arm_group>
    <arm_group_label>C-Section with spinal Duramorph</arm_group_label>
    <description>Duramorph with supplemental oxycodone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C-Section with spinal Duramorph and subcutaneos bupivacaine</arm_group_label>
    <description>Duramorph with subcutaneous bupivacaine with supplemental oxycodone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C-Section spinal Duramorph and subcutaneous marcaine and epi</arm_group_label>
    <description>Duramorph with subcutaneous bupivacaine with epinephrine and supplemental oxycodone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone Hcl 15Mg Tab</intervention_name>
    <description>. Roxicodone (oxycodone hydrochloride) is a narcotic pain reliever used to treat moderate to severe pain. The extended-release form of Roxicodone is for around-the-clock treatment of pain. Roxicodone is available in generic form.</description>
    <arm_group_label>C-Section with spinal Duramorph</arm_group_label>
    <arm_group_label>C-Section with spinal Duramorph and subcutaneos bupivacaine</arm_group_label>
    <arm_group_label>C-Section spinal Duramorph and subcutaneous marcaine and epi</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant patients undergoing C-Section under spinal anesthesia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  elective cesarean delivery

          -  planned spinal anesthesia

        Exclusion criteria:

          -  Non-English speaking

          -  Urgent or emergent cesarean delivery

          -  Active labor [defined as: &gt;4cm cervical dilation or regular contractions noted on
             tocometer (&gt;2 contractions in a 10 minute period for 30 consecutive minutes)]

          -  Chronic antepartum opioid use

          -  History of substance abuse (alcohol or drug)

          -  Current tobacco use

          -  Chronic steroid use
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women undergoing Cesarean Section under spinal anesthesia</gender_description>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2017</study_first_submitted>
  <study_first_submitted_qc>December 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Jeffrey Bernstein</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
    <mesh_term>Pain, Referred</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Publish Article</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

